- Trials with a EudraCT protocol (26,162)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (9,945)
26,162 result(s) found for: NA.
Displaying page 982 of 1,309.
EudraCT Number: 2011-000106-22 | Sponsor Protocol Number: GE012-098 | Start Date*: 2011-09-01 | |||||||||||||||||||||
Sponsor Name:GE Healthcare Ltd. and its affiliates | |||||||||||||||||||||||
Full Title: A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography | |||||||||||||||||||||||
Medical condition: Patients that are referred to undergo a peripheral arterigraphy as part of their routine clinical care. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005457-25 | Sponsor Protocol Number: PCN-101-21 | Start Date*: 2021-08-30 | |||||||||||
Sponsor Name:Perception Neuroscience, Inc | |||||||||||||
Full Title: A randomized, placebo-controlled, double-blind study to assess the safety and efficacy of intravenous PCN-101 in treatment-resistant depression | |||||||||||||
Medical condition: Treatment-resistant depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003736-77 | Sponsor Protocol Number: IRFMN-OVA-7814 | Start Date*: 2020-06-10 | ||||||||||||||||
Sponsor Name:Istituto di Ricerche Farmacologiche Mario Negri IRCCS | ||||||||||||||||||
Full Title: A multicenter, open-label phase II trial of a new customized dosing (Rational Adjustment of Dose to reduce Adverse Reactions “RADAR” dosing) of niraparib as maintenance therapy in platinum sensitiv... | ||||||||||||||||||
Medical condition: Ovarian, fallopian tube or primary peritoneal recurrent cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DE (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005315-44 | Sponsor Protocol Number: D8851C00001 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults | |||||||||||||
Medical condition: COVID-19 (Coronavirus Disease 2019) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Ongoing) HU (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005150-62 | Sponsor Protocol Number: GALEN | Start Date*: 2013-05-14 | |||||||||||||||||||||
Sponsor Name:GELARC | |||||||||||||||||||||||
Full Title: A Phase Ib/II study of OBINUTUZUMAB combined with LENALIDOMIDE for the treatment of relapsed/refractory follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma. | |||||||||||||||||||||||
Medical condition: Phase IB: CD20 positive Follicular Lymphoma, WHO grade 1, 2 or 3a relapsed/refractory after ≥1 prior R-containing regimen Phase II: CD20 positive follicular and agressive B-cell lymphoma (Diffus... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Ongoing) BE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002409-23 | Sponsor Protocol Number: CLN-081-001(REZILIENT1) | Start Date*: 2020-02-27 | ||||||||||||||||
Sponsor Name:Cullinan Oncology Inc. | ||||||||||||||||||
Full Title: A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Locally-Advanced or Metastatic Non-Small C... | ||||||||||||||||||
Medical condition: Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003344-74 | Sponsor Protocol Number: HOVON116 | Start Date*: 2013-11-12 | ||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||
Full Title: A phase I/II feasibility study of panoninostat alone and the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with... | ||||||||||||||||||
Medical condition: (very) poor risk AML or RAEB with IPSS ≥ 1.5 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) BE (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001642-18 | Sponsor Protocol Number: D8230C00002 | Start Date*: 2021-05-13 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies | |||||||||||||
Medical condition: Haematological Malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Temporarily Halted) ES (Temporarily Halted) FR (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003602-16 | Sponsor Protocol Number: PM1183-A-014-15 | Start Date*: 2022-08-18 | |||||||||||
Sponsor Name:PHARMA MAR, S.A. SOCIEDAD UNIPERSONAL | |||||||||||||
Full Title: Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors. | |||||||||||||
Medical condition: Selected Advanced Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) DE (Ongoing) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003149-41 | Sponsor Protocol Number: IgPro20_2001 | Start Date*: 2019-07-16 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Multicenter, Randomized, Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20 (subcutaneous immunoglobulin, Hizentra®) and IgPro10 (intravenous immunoglob... | |||||||||||||
Medical condition: Safety and Pharmacokinetics in subjects with diffuse cutaneous systemic sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001184-25 | Sponsor Protocol Number: WN42444 | Start Date*: 2022-01-31 | |||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GANTENERUMAB IN PARTICIPANTS AT RISK FOR OR AT THE EARLIEST STAGE... | |||||||||||||
Medical condition: Alzheimer's Disease (AD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) SE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021215-16 | Sponsor Protocol Number: H9P-MC-LNBQ | Start Date*: 2011-02-17 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients with Major De... | |||||||||||||
Medical condition: Major depressive disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) FI (Completed) SK (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001012-35 | Sponsor Protocol Number: G200802 | Start Date*: 2015-10-06 | ||||||||||||||||||||||||||
Sponsor Name:GTx, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in... | ||||||||||||||||||||||||||||
Medical condition: Estrogen Receptor Positive and Androgen Receptor Positive Breast Cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: BG (Prematurely Ended) HU (Ongoing) LT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004152-22 | Sponsor Protocol Number: DEX-TRA-06 | Start Date*: 2016-03-01 | |||||||||||
Sponsor Name:MENARINI RICERCHE S.p.A. | |||||||||||||
Full Title: Analgesic efficacy of oral dexketoprofen trometamol/tramadol hydrochloride versus tramadol hydrochloride/paracetamol: a randomised, double-blind, placebo and active-controlled, parallel group study... | |||||||||||||
Medical condition: moderate to severe acute pain after removal of impacted lower third molar | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) ES (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006657-63 | Sponsor Protocol Number: 0881K1-4500-EU (B1801016) | Start Date*: 2009-05-08 | |||||||||||
Sponsor Name:Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom | |||||||||||||
Full Title: Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA). | |||||||||||||
Medical condition: Rheumatoid Arthritis (RA) patients who are on Etanercept (ETN) treatment and are in remission or in a Low Disease Activity (LDA) state | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) DK (Completed) HU (Completed) IS (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003463-22 | Sponsor Protocol Number: AI452-030 | Start Date*: 2013-03-13 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: MAGNITUDE - A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who... | |||||||||||||
Medical condition: Chronic Hepatitis C Virus Infection (Genotype 1b, 2, 3, 4) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: ES (Temporarily Halted) IT (Prematurely Ended) NL (Completed) FR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000207-24 | Sponsor Protocol Number: BO39694 | Start Date*: 2017-05-16 | ||||||||||||||||
Sponsor Name:Roche Farma S.A.U. que realiza el ensayo en España y que actúa como representante de F.Hoffmann-La Roche Ltd. | ||||||||||||||||||
Full Title: A MULTICENTER, INTERNATIONAL, ROLLOVER STUDY OF ALECTINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE OR REARRANGED DURING TRANSFECTION (RET)-POSITIVE CANCER | ||||||||||||||||||
Medical condition: Anaplastic lymphoma kinase (ALK)-positive or rearranged during transfection (RET)-positive cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) FR (Ongoing) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023956-99 | Sponsor Protocol Number: IM133-001 | Start Date*: 2011-08-17 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotre... | |||||||||||||
Medical condition: RHEUMATOID ARTHRITIS,NOS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) NL (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003988-10 | Sponsor Protocol Number: GS-US-380-1490 | Start Date*: 2016-02-18 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infec... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000452-18 | Sponsor Protocol Number: ETB115J2411 | Start Date*: 2018-09-26 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (... | ||||||||||||||||||
Medical condition: immune thrombocytopenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) GR (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.